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Abstract
Patients with glioblastoma multiforme (GBM) exhibit a deficient anti-tumor immune response. Both arms of the
immune system were shown to be hampered in GBM, namely the local cellular immunity mediated by the Th1
subset of helper T cells and the systemic humoral immunity mediated by the Th2 subset of helper T cells.
Immunotherapy is rapidly becoming one of the pillars of anti-cancer therapy. GBM has not received similar clinical
successes as of yet, which may be attributed to its relative inaccessibility (the blood-brain barrier (BBB)), its poor
immunogenicity, few characterized cancer antigens, or any of the many other immune mechanisms known to be
hampered. Focused ultrasound (FUS) is emerging as a promising treatment approach. The effects of FUS on the
tissue are not merely thermal. Mounting evidence suggests that in addition to thermal ablation, FUS induces
mechanical acoustic cavitation and immunomodulation plays a key role in boosting the host anti-tumor immune
responses. We separately discuss the different pertinent immunosuppressive mechanisms harnessed by GBM and
the immunomodulatory effects of FUS. The effect of FUS and microbubbles in disrupting the BBB and introducing
antigens and drugs to the tumor milieu is discussed. The FUS-induced pro-inflammatory cytokines secretion and
stress response, the FUS-induced change in the intra-tumoral immune-cells populations, the FUS-induced
augmentation of dendritic cells activity, and the FUS-induced increased cytotoxic cells potency are all discussed. We
next attempt at offering a conceptual synopsis of the synergistic treatment of GBM utilizing FUS and
immunotherapy. In conclusion, it is increasingly apparent that no single treatment modality will triumph on GBM.
The reviewed FUS-induced immunomodulation effects can be harnessed to current and developing
immunotherapy approaches. Together, these may overcome GBM-induced immune-evasion and generate a
clinically relevant anti-tumor immune response.
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Background
Glioblastoma multiforme (GBM) is the most common
primary malignant brain tumor in adults. Despite stand-
ard of care treatment, the median survival of a patient
harboring a GBM is less than 2 years. Although subdi-
vided to different subtypes, these overall grim prognosis
figures have stood fast and changed very little in the past
few decades, proving resistant to most developments
and revolutions incurred on modern medicine [1–3].
Current day first-line treatment for GBM patients in-
cludes a combination of surgery, chemotherapy, and
radiotherapy [1–3]. Recent understanding of the role of
epigenetic inheritance (e.g., promoter methylation) adds
complexity to this issue. O6-methylguanine-DNA meth-
yltransferase (MGMT) is a key repair enzyme that
contributes to the resistance of tumors to alkylating
agents (carmustine or temozolomide). MGMT promoter
methylation silences the gene, thereby increasing the
susceptibility of the tumor cells to these agents [1–3].
The unique nature of GBM and its inherent challen-
ging features was evident as early as 80 years ago. In the
1930s, neurosurgeon Walter Dandy reported recurrence
of contralateral GBM even after a hemispherectomy,
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emphasizing thus how infiltrative these tumors are. Pa-
tients with GBM exhibit a deficient anti-tumor immune
response. Early reports of GBM patients with a post-
operative surgical site infection who exhibit longer sur-
vival served as the first hint, sparking an interest in the
topic. This phenomena was initially attributed to the
non-specific immune recruitment invoked by the local
bacterial lipopolysaccharide (LPS), targeting the tumor
as well to some extent. Since these pivotal observations,
a plethora of studies characterizing the immunosuppres-
sive mechanisms in GBM have been conducted [3–19].
As discussed later, both arms of the immune system
were shown to be hampered in GBM, namely the local
cellular immunity mediated by the Th1 subset of helper
T cells, and the systemic humoral immunity mediated by
the Th2 subset of helper T cells [7, 8].
Immunotherapy is rapidly becoming one of the pillars
of anti-cancer therapy. Its targeted nature and reduced
treatment related toxicity, stemming from recruiting and
activating own selective cytotoxic mechanisms, makes it
intuitively an attractive option. GBM has not received
similar clinical successes as of yet. This may be attrib-
uted to its relative inaccessibility (protected by the BBB),
its poor immunogenicity, few characterized cancer anti-
gens, or any of the many other immune mechanisms
known to be hampered, briefly discussed next [3–19].
Preclinical studies suggest that immunotherapies can
elicit significant anti-tumor responses in GBM, over-
coming some of the barriers and tumor-related escape
mechanisms, while others fail at specific points. More-
over, immunotherapies may have the potential to work
synergistically with other treatment modalities such as
high-intensity focused ultrasound (HIFU), surgery,
radiotherapy, or alkylating agents.
Continuous-wave (CW) high-intensity focused ultra-
sound (HIFU) is emerging as a promising treatment ap-
proach. CW-HIFU is the only noninvasive thermal
technique that allows for real-time imaging of the treat-
ment progress using MR thermometry [20]. High-energy
ultrasound beams are applied to focus acoustic energy
on a well-defined region. Although, single ultrasound
beams penetrate a tissue without causing any significant
heat, focusing beams from multiple directions into a se-
lected region results in a temperature rise (to >60 °C),
and subsequently inducing coagulative necrosis [20–23].
Ultrasonic energy emitted from concave piezoelectric
ceramics can be tightly focused with radial and axial di-
mensions of only 1–2 and 10–20 mm, respectively,
based on the range of frequencies and transducer geom-
etry. Complete tumor ablation is then achieved by
employing multiple stereotactic sonications [20, 23–25].
The effects of FUS on the tissue are not merely ther-
mal. Mounting evidence suggests that in addition to the
thermal ablation mechanism, HIFU induces mechanical
acoustic cavitation which has both mechanical and mo-
lecular implications and also boosts the host anti-tumor
immune responses (Table 1) [26–47]. We will briefly
review separately the different pertinent immunosup-
pressive mechanisms harnessed by GBM and the immu-
nomodulatory effects of HIFU. Of note, many such
HIFU-related mechanisms were shown for non-GBM tu-
mors. We will next attempt at offering a conceptual syn-
opsis of the synergistic treatment of GBM utilizing
HIFU and immunotherapy.
Pertinent facts in immunology and brain-cancer
immunotherapy
The initial interaction of the T cell receptor (TCR) with
the major histocompatibility complex (MHC)-peptide
complex is stabilized by the binding of CD4+ or CD8+
co-receptors molecules (termed as signal 1) [48]. This
interactions are accompanied by the interaction of other
receptors (termed as co-stimulatory or co-inhibitory sig-
nals), a process termed as signal 2. Efficient T cell activa-
tion requires as little as a single MHC-peptide complex
for CD4+ T-helper cells and as little as 10 for cytotoxic
T cells (CTLs) [49], yet a signal 1 interaction that lacks a
stimulatory signal 2 will fail to elicit T cell activation and
differentiation. Different co-stimulatory (e.g., CD28) and
co-inhibitory (e.g., CTLA-4) signal 2 molecules directs
differentiation to different avenues, ranging from a po-
tent anti-tumor response (in CD28 activation), to anergy
and even apoptosis (upon CTLA-4 or Fas activation)
[48]. A local cytokine based pro-inflammatory or anti-
inflammatory milieu plays a significant role in driving
the immune response as well.
Mounting an effective brain anti-tumor immune re-
sponse requires that certain requirements are met. As
discussed later, the GBM cells developed mechanisms to
evade or block every one of the following: first, the ef-
fector T cells, antibodies, or cytokines must penetrate
the brain parenchyma before reaching the tumor bed.
This entails crossing in active state through the BBB
[50]. Some authors claim that the BBB is compromised/
disrupted in the vicinity of the GBM [9] while others
consider it a potent obstacle. Next, tumor-associated tar-
get antigens must be sufficiently different from self-
antigens. Third, tumor cells must express sufficient
MHC molecule to mount a specific CTLs effector-
mediated response. Fourth, a local inflammatory re-
sponse should then be instigated and properly regulated.
Fifth, CTLs and TH1 cells must retain their anti-tumor
effector function during migration through the brain
parenchyma and its resident cells. The local cytokine
microenvironment should support the T cell function.
Finally, effector cell functionality must be retained dur-
ing the encounter with the tumor cells, not suppressed
actively or passively by the tumor cells.
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Table 1 Focused ultrasound immunomodulatory effect—literature review
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Immune mechanisms hampered in GBM
A multitude of immunosuppressive mechanisms (both
active and passive) as well as immune-evasion tech-
niques are attributed to GBM cells (refer to Fig. 1)
[3–19]. GBM patients were shown to exhibit overall low
number of circulating T cells, rendering them vulnerable
to any systemic challenge (infection, allergic reaction, or
response to tumors) [10]. Fecci et al. [11] noted an abnor-
mally high proportion (>2.5-fold increase) of circulating
inhibitory Treg cells (CD4
+FoxP+) populations in GBM pa-
tients, unrelated to the co-administration of glucocorti-
coids [11]. The relative proportion of circulating Treg cells
is known to linearly correlate with in vitro suppression of
effector T cell activation [12]. The most common genetic
alteration in GBM (occurring in 80~95 % of tumors) is
the loss of heterozygosity in chromosome #10 [7, 8, 13,
14]. Loss of the PTEN gene (phosphatase and tensin
homologue) in this affected locus (10q23.3), serving as an
inhibitor of the Phospho-inositol-3 kinase-signalling path-
way may mediate a decrease in tumor cell immunogen-
icity by increasing the expression of B7-H1 (a co-
inhibitory signal 2 molecule discussed previously), as well
as increases anti-inflammatory (TH2 type) cytokines re-
lease [13, 14]. These mechanisms independently support
the evolution of anergy and tolerance to the tumor.
Multiple genetic pathways, involved in cell-cycle regu-
lation, growth-factor receptors presentation, and cyto-
kine formation and regulation are known to be affected
in GBM. Such pathways include the p16/pRb/CDK4
pathway, the p53/MDM2/p14ARF pathway, the epider-
mal growth factor receptor (EGF-R) gene [with unique
variants like the EGFRvIII, responsive to Erlotinib],
platelet-derived growth factor receptor (PDGF-R), and
PI3-kinase/PTEN cascades [13, 14]. An immune-evasion
mechanism suggested is the tumor’s ability to downregu-
late or express low levels of class-I MHC [15], hiding its
existence from the cellular arm of the immune system,
thus not detected by CD4+ T helper cells or CD8+ CTLs.
This feature of immune evasion is compounded by the
GBM ability to express aberrant non-classical MHC
class I molecules (class Ib) termed as HLA-G. These
decoy MHC molecules are structurally related to the
classical MHC molecules (the class-Ia composed of
HLA-A, HLA-B, HLA-C). HLA-G expression, renders
tumor cells highly resistant to direct CTL-mediated
alloreactive lysis, inhibits the alloproliferative response,
and prevents efficient priming of cytotoxic T cells [16].
Additional GBM-related mechanisms involve the
upregulation of anti-apoptotic proteins by the GBM
tumor cells [17], rending the tumor cells immortal (e.g.,
Fig. 1 Synopsis. The key established mechanisms hampered in GBM and the key immune-modulating effects of HIFU are presented. A theoretical
action-reaction scheme is presented, connecting certain known GBM-evasion mechanisms with the FUS-induced counter response. Note that a
single FUS-induced effect may influence a multitude of immunosuppressive mechanisms and vice versa. Refer to text
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unresponsive to death signals). Synergistically with all
mentioned is the tumor-induced, cytokine driven, local
immunosuppressive microenvironment. Reduced levels
of pro-inflammatory cytokines (those driving to the TH1
differentiation) and increased local concentrations of
anti-inflammatory cytokines and mediators (those driv-
ing to the TH2 differentiation) drive both the tissue and
immune-elements that manage to reach the tumor site
into an inactive or dysfunctional state [18]. Cytokines se-
creted, be it directly or indirectly by the GBM tumor
cells, mediate immune-anergy and tumor proliferation
[10, 19]. Of note, the complex interplay between the dif-
ferent mechanisms stated is complex and largely
unknown.
FUS-induced anti-tumor effects
Focused ultrasound exerts an anti-tumor effect utilizing
three distinct complementary “modes” of action: thermal
ablation, acoustic cavitation, and immunomodulation.
Thermal ablation, the most obvious and characterized
mode, is similar to many other lesional technologies in
that the tissue at the focal point is targeted with the goal
of causing coagulative necrosis. The second mechanism,
acoustic cavitation, is in essence mechanical lysis of the
tissue caused by harnessing acoustic cavitation, namely
the rapid expansion and contraction of microbubbles/
gaseous nuclei in cells through acoustic pressure within
the targeted tissue [51]. This process enhances the local
heating [52] as well as leads to collapse of the intracellular
machinery (i.e., mitochondria, endoplasmic reticulum, as
well as nuclear and cell membranes) [20]. Harnessing the
advantages of mechanical cavitation, the FUS aided dis-
ruption of the BBB (at lower exposure) serves as another
synergistic mechanism to prime an anti-GBM response
(discussed next) [53, 54]. In addition to disrupting the
BBB, these micro-bubbles can potentially be loaded with
tumor antigens, allowing for immune-homing, mounting
a more focused, effective immune response [53–55]. The
third mechanism employs sub-lethal mild hyperthermia,
i.e., a uniform low-level heating of a region of interest [39,
56, 57]. Pulsed-mode HIFU with negative pressures equal
or higher than that used for thermal ablation (7–12 MPa)
was shown to boost the systemic anti-tumor immune re-
sponse through multiple mechanisms (Table 1) [26–47].
Immunologically speaking, although considered different,
each of these modes shares a final common pathway in
terms of initiating an immune response. This response is
instigated through the release of tumor debris rich in
unique antigens and danger signals into the inter-cellular
matrix [51].
FUS-induced immuno-modulating effects
Many preclinical and clinical studies have demonstrated
that FUS can facilitate and amplify an immune anti-
tumor response, prolonged overall survival and protec-
tion from growth of new tumors when re-challenged
(Table 1) [26–47]. One should note that all immune-
modulating effects discussed hereafter were described on
other tumor types. The assumption that these effects are
FUS/HIFU based and are tumor type independent, was
not validated objectively. All three HIFU-related modes
of action can be assigned an immune-modulating mech-
anism. The HIFU-induced thermal ablation causes sur-
viving tumor cells to upregulate danger signals such as
heat shock proteins (HSP) and adenosine triphosphate
(ATP). HSPs have long been viewed as potent innate im-
munity tools, serving to increase the tumor immunogen-
icity [30, 31, 58]. Second, mechanical cavitation allows
for better BBB penetration for antigens and immune
cells as well as results in lysis-related tumor debris.
These debris serve then as potent antigens for the im-
mune system, activating dendritic cells (DCs) [29].
Third, FUS mitigates tumor-induced immunosuppres-
sion. We will now briefly discuss each of the last two
proposed mechanisms. A thorough discussion of the dir-
ect ablative thermal effect is not in the scope of this re-
view. Table 1 presents a brief overview of key preclinical
and clinical studies, per different tumor type, segregated
based on the proposed FUS-induced immunomodula-
tory effect. Of note, this table is not restricted to
studies conducted in GBM or in the CNS, rather
serves as a proof of concept for FUS-based immune-
triggered events.
Microbubbles and BBB disruption
The addition of microbubbles (MB) to FUS can help
generate more local heating in the area of focus [52], but
at lower exposures, FUS with MB can be used solely for
BBB disruption. These microbubbles, delivered intraven-
ously, are composed of lipid-encased perfluorocarbon
gas, and measure approximately 1–5 μm in diameter
[59]. Recent reports suggest that the permeability of the
blood vessels can be substantially increased by FUS in
the presence of MB. Even at greatly reduced acoustic
pressures, barely above the pressure thresholds employed
in diagnostic ultrasound, these MBs can be used to
enhance targeted delivery of chemotherapeutic agents
[60–63]. FUS exposure bursts of 10 ms, repeated at a fre-
quency of 1 Hz and used for 20–30 s durations are the
typical settings used. FUS with MB impose mechanical
forces on the vascular endothelium which then results in
a transient opening of the inter-endothelial tight junctions
[64]. This translates to a local and reversible BBB disrup-
tion. The size and resonance frequency of the microbub-
bles can be altered, allowing for agents up to 2000 kDa to
enter, in order to facilitate different goals [65]. Larger
microbubbles require less acoustic pressure to achieve
BBB opening. The FUS and MB BBB-disruption effects
Cohen-Inbar et al. Journal of Therapeutic Ultrasound  (2016) 4:2 Page 5 of 9
last for several hours and can be localized to the tumor re-
gion, prior to returning to the pre-FUS state [66]. Dy-
namic contrast-enhanced MRI has been shown to be able
to monitor the kinetics of BBB disruption [67].
Several preclinical studies have demonstrated the feasi-
bility of BBB disruption by FUS and MB for the adminis-
tration of chemotherapeutics in the treatment of glioma.
Aryal et al. [68] demonstrated increased survival in a rat
glioma model, upon treatment with a combination of
FUS and liposomal doxorubicin. Such liposomal doxo-
rubicin would not cross the BBB without FUS-mediated
disruption. Liu et al. [69] reported an increased concen-
tration of temozolomide in a glioma model after FUS,
which correlated with a diminished tumor progression
and increased animal survival [69]. Yang et al. [70]
reported the successful use of HIFU in delivering
interleukin-4 (IL-4) receptor-targeted liposomal doxo-
rubicin for enhanced targeted drug delivery and anti-
tumor effect in GBM mouse model [70]. FUS with MB
method of BBB disruption was shown to be applicable in
delivering nanoparticles, DNA, plasmid vectors, and
antibodies [71, 72].
Chen et al. [73] reported their successful preclinical
feasibility study of FUS-induced BBB disruption in order
to enhance IL-12 delivery in a C-6 glioma rat model.
FUS-induced BBB opening had no obvious effect on the
T lymphocytes population in normal animals, either in
the brain or systemically. Yet, it triggered mild changes
in the tumor-infiltrating lymphocyte (TIL) population,
particularly in numbers of CD3+CD8+ CTLs in the
tumor region. IL-12 administration triggered a profound
increase in all TIL populations, including CD3+CD4+ T
helper cells, CTLs, and CD4+CD25+ Treg. The combined
FUS-BBB opening with IL-12 administration produced
the most significant IL-12 increase, CTL increase and
CTL/Treg ratio increase, thus contributing to the most
significant suppression of tumor progression and in-
creased animal survival. These reports provided evidence
that FUS-mediated BBB opening can enhance immune-
modulating agent delivery to the brain.
Cytokines and stress response
HSPs are intracellular molecular chaperones, able to bind
tumor peptide antigens and enhance tumor cell immuno-
genicity [74–79]. Antigen-presenting cells (APCs; namely
DCs, macrophages and CD4+ T helper cells) endocytose
the HSP-tumor peptide complex and present the chaper-
oned peptides directly to tumor-specific CTLs. This
evokes potent cellular immune responses against tumor
cells [74–79]. Autologous HSP-peptide complexes gener-
ated from a single individual tumor were shown to gener-
ate a therapeutic immune response in animal models [39].
Because random mutations in GBM cells usually produce
patient-unique tumor associated antigens, HSP vaccination
may be a rationally personalized approach that may obviate
the requirement to identify the unique antigens [74–79].
HIFU was shown to upregulate the expression of
HSP70 both in vitro and ex vitro [30, 31, 42]. An in-
creased HSP-70 expression was detected on the surviv-
ing cell membrane of 23 patients with breast cancer
treated with HIFU ablation. HSP expression was mainly
found in the central necrosis zone, with only sparse
positively stained cells observed in the periphery [39].
The most striking change noted was the positive expres-
sion of EMA and HSP-70 on the treated cancer cells in
all 23 patients after HIFU ablation [39]. EMA is a known
mucinous glycoprotein considered as a differentiation
tumor marker and a histological prognostic agent.
Peripheral and intra-tumoral immune cell populations
FUS was shown to enrich the TILs population in
immune-potent pro-inflammatory potent anti-tumor ef-
fector cells. In human breast cancer specimens collected
1–2 weeks after FUS treatment [45], a significant in-
crease in TILs of both T and B subsets at the margin of
the ablated region was shown, as compared to FUS-
untreated tumor samples. Immunohistochemistry ana-
lysis showed that a subset of these cells was activated
CTLs (CD57+), expressing perforin and granzyme B
molecules, indicative of a cytotoxic effector function
[45]. A randomized study of 48 patients comparing those
who underwent FUS treatment prior to radical mastec-
tomy to patients who underwent surgery alone showed
that those who had received FUS treatment prior to sur-
gery had a significantly higher level of TILs of T, B, and
NK cells subsets [80].
This TILs enrichment phenomenon is not limited to
breast cancer. It was shown in patients treated with FUS
suffering posterior uveal melanoma [35], pancreatic car-
cinoma [37], osteosarcoma [32], hepatocellular carcin-
omas (HCC) [32], and RCC [32]. Some combination of
increased percentages of CD3+ T cells, CD4+ T cells, a
higher CD4+/CD8+ ratio, or NK cell stimulation [37]
were observed [32, 35]. Refer to Table 1 for review of
landmark studies and related mechanisms.
Augmentation of dendritic cell activity
FUS was shown to enhance the infiltration capabilities
of dendritic cells (DCs) [15, 18] as well as other antigen
presenting cells [44] in the treated tumor. Enhanced in-
filtration was followed subsequently with DCs migration
to the draining lymph nodes, presenting tumor-
associated antigens to a wide variety of circulating T
cells [26, 43]. Zhang et al. [33] demonstrated that tumor
debris induced by HIFU could serve as an effective im-
munogenic vaccine. This vaccine was shown to elicit
tumor-specific immune responses, including induction
of CTL cytotoxic activity, DCs-enhanced activation, and
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to protect naïve mice against a lethal tumor challenge.
When tumor debris were loaded with immature DCs,
this vaccine could induce maturation of DCs to a signifi-
cant extent as well as increased CTLs cytotoxicity (man-
ifested by elevated TNF-α and IFN-γ secretion) [29].
The authors noted that while this vaccine was able to
initiate a host specific immune response after H22 chal-
lenge in the vaccinated mice which resulted in tumor
growth rate reduced, no survival advantage could be ob-
served [29]. Thus, HIFU induces activation and stimula-
tion of various APCs, leading to an increased expression
of costimulatory molecules and enhanced secretion of
IL-12 (via DCs) and TNF-α (macrophages) [30]. The po-
tency of dendritic cell infiltration and activation was
shown to be further improved when sparse-scan mode
FUS was used compared to dense-scan mode [46, 53],
yet a detailed technical and physical discussion of FUS
modes is beyond the scope of this review.
Resistances to tumor re-challenge and increased CTLs
potency
A portion of the immunomodulatory effects of FUS
noted in different reports are lacking exact molecular
mechanisms as of yet, collectively termed as resistance
to tumor re-challenge. Some overlap with CTLs potenti-
ation is suspected and hence these mechanisms are dis-
cussed together. Zhang et al. [33] reported their results
with mice implanted with an HIFU-treated H22 hepato-
cellular carcinoma (HCC) tumor cells. The animals re-
ceived a subcutaneous tumor challenge 10 days after
vaccination. Tumor growth was significantly delayed in
mice vaccinated with previously HIFU-treated tumor
cells. Mice that were treated with HIFU showed an 88 %
survival rate at 60 days as compared to 36 and 16 % for
the sham-HIFU and control groups, respectively [33,
46]. Survival, however, was not different between the
groups [33]. Other mouse models concurred with this
observation and have shown a significant decrease in the
growth rate of tumors during a second challenge [34].
Yang et al. [34] reported the use HIFU to treat C1300
neuroblastoma cells implanted in mouse flanks, followed
by the re-challenge of the same tumor cells. The authors
noted a significantly slower growth of re-implanted
HIFU-treated tumors compared with the controls.
Several reports of potentiated CTLs effector activity and
potency after HIFU support this mechanism (Table 1). In-
creased effector function can be measured by increased
IFNγ and TNFα secretion [26, 28, 29] or increased direct
CTLs-mediated cytotoxicity [43]. Xia et al. [28] reported
that the cytotoxicity of CTLs and the number of activated
tumor-specific CTLs was significantly increased in the
H22 tumor bearing mice treated with HIFU. Adoptive
transfer of the activated lymphocytes was shown to pro-
vide better long-term survival and lower metastatic rates
in the mice re-challenged by the same tumor cells as com-
pared with sham-HIFU and control groups, due to the in-
duced anti-tumor cellular immunity in the mice [28].
Similar results were reported in mice implanted MC-38
colorectal adenocarcinoma (CRC) and melanoma after
HIFU ablation. HIFU treatment was shown to induce an
enhanced CTLs activity in vivo, providing protection
against subsequent tumor re-challenge [26, 43].
Synopsis and future directions
In an attempt to direct hypothesis-based approach to FUS-
induced immunomodulation in GBM, the key established
mechanisms hampered in GBM and the key immune-
modulating effects of FUS discussed in this review are pre-
sented in Fig. 1. A theoretical action-reaction scheme is
presented; connecting certain known GBM-evasion mech-
anisms with the FUS-induced counter response. A single
FUS-induced effect may influence a multitude of immuno-
suppressive mechanisms and vice versa. This scheme is
given in an attempt to present a theoretical basis for the ef-
fectiveness of HIFU immunomodulation and synergistically
supporting immunotherapies overcoming many of the
GBM mediated immune-resistance mechanisms.
Future research still needs to be done to both dissect
the different FUS-induced molecular and immunological
mechanisms at play. Further research is needed to
optimize the FUS treatment method, find other combin-
ational therapies, defining how to most effectively use it
in combination with immunotherapy [51].
Conclusions
No single treatment modality will cure GBM. It is increas-
ingly apparent that surgery alone, HIFU ablation, chemo-
therapy, or immunotherapy will not solely triumph. We
reviewed the FUS-induced immunomodulation effect,
which can be harnessed to the current and developing im-
munotherapies approaches. Together, these modalities may
overcome GBM-induced immune-evasion and generate a
clinically relevant anti-tumor immune response. Further
study to the synergistic collaboration of different thera-
peutic approaches and the elaborated molecular immune
interplay will shed light on this formidable challenge.
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